Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose reduction and withdrawal of adalimumab or etanercept versus usual care in rheumatoid arthritis
NL-OMON38325Active, not recruiting
- Sponsor
- Sint Maartenskliniek
- Start
- Dec 2011
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of adalimumab and etanercept in rheumatoid arthritis (RA) (2 arms), sponsored by Sint Maartenskliniek. Primary endpoints: Cumulative incidence of persistent rheumatoid arthritis flares at 18 months and Cumulative incidence of flare. Started Dec 2011; status: active, not recruiting.
02
Drugs
adalimumabetanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON38325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38325.